Cargando…

A three-protein signature and clinical outcome in esophageal squamous cell carcinoma

Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Hui-Hui, Zhang, Shi-Yi, Shen, Jin-Hui, Wu, Zhi-Yong, Wu, Jian-Yi, Wang, Shao-Hong, Li, En-Min, Xu, Li-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467159/
https://www.ncbi.nlm.nih.gov/pubmed/25605255
_version_ 1782376338025349120
author Cao, Hui-Hui
Zhang, Shi-Yi
Shen, Jin-Hui
Wu, Zhi-Yong
Wu, Jian-Yi
Wang, Shao-Hong
Li, En-Min
Xu, Li-Yan
author_facet Cao, Hui-Hui
Zhang, Shi-Yi
Shen, Jin-Hui
Wu, Zhi-Yong
Wu, Jian-Yi
Wang, Shao-Hong
Li, En-Min
Xu, Li-Yan
author_sort Cao, Hui-Hui
collection PubMed
description Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemistry-based three-protein signature model in patients with ESCC. We determined the protein expression of Annexin II, cofilin 1, ezrin, fascin, kindlin-2, moesin, MTSS1, myosin-9, profilin-1, Rac1, radixin, ROCK2, talin, tensin and villin 1 in a test cohort including 110 formalin-fixed, paraffin-embedded esophageal curative resection specimens by tissue microarrays (TMAs). A three-protein signature elicited from the protein cluster, Annexin II, kindlin-2, and myosin-9, was validated by TMAs on an independent cohort of 147 specimens. The expression of three-protein signature was highly predictive of ESCC overall survival (OS) and disease-free survival (DFS) in both generation and validation datasets. Regression analysis shows that this three-protein signature is an independent predictor for OS and DFS. Furthermore, the predictive ability of these 3 biomarkers in combination is more robust than that of each individual biomarker. This study demonstrates a clinically applicable prognostic model that accurately predicts ESCC patient survival and/or tumor recurrence, and thus could serve as a complement to current risk stratification approaches.
format Online
Article
Text
id pubmed-4467159
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-44671592015-06-22 A three-protein signature and clinical outcome in esophageal squamous cell carcinoma Cao, Hui-Hui Zhang, Shi-Yi Shen, Jin-Hui Wu, Zhi-Yong Wu, Jian-Yi Wang, Shao-Hong Li, En-Min Xu, Li-Yan Oncotarget Clinical Research Paper Current staging is inadequate to precisely predict clinical outcome of esophageal squamous cell carcinoma (ESCC) and determine treatment choices, which vary from operation alone to intensive multimodal regimens. The purpose of this study is to investigate the prognostic values of an immunohistochemistry-based three-protein signature model in patients with ESCC. We determined the protein expression of Annexin II, cofilin 1, ezrin, fascin, kindlin-2, moesin, MTSS1, myosin-9, profilin-1, Rac1, radixin, ROCK2, talin, tensin and villin 1 in a test cohort including 110 formalin-fixed, paraffin-embedded esophageal curative resection specimens by tissue microarrays (TMAs). A three-protein signature elicited from the protein cluster, Annexin II, kindlin-2, and myosin-9, was validated by TMAs on an independent cohort of 147 specimens. The expression of three-protein signature was highly predictive of ESCC overall survival (OS) and disease-free survival (DFS) in both generation and validation datasets. Regression analysis shows that this three-protein signature is an independent predictor for OS and DFS. Furthermore, the predictive ability of these 3 biomarkers in combination is more robust than that of each individual biomarker. This study demonstrates a clinically applicable prognostic model that accurately predicts ESCC patient survival and/or tumor recurrence, and thus could serve as a complement to current risk stratification approaches. Impact Journals LLC 2014-12-31 /pmc/articles/PMC4467159/ /pubmed/25605255 Text en Copyright: © 2015 Cao et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Cao, Hui-Hui
Zhang, Shi-Yi
Shen, Jin-Hui
Wu, Zhi-Yong
Wu, Jian-Yi
Wang, Shao-Hong
Li, En-Min
Xu, Li-Yan
A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
title A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
title_full A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
title_fullStr A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
title_full_unstemmed A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
title_short A three-protein signature and clinical outcome in esophageal squamous cell carcinoma
title_sort three-protein signature and clinical outcome in esophageal squamous cell carcinoma
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467159/
https://www.ncbi.nlm.nih.gov/pubmed/25605255
work_keys_str_mv AT caohuihui athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT zhangshiyi athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT shenjinhui athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT wuzhiyong athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT wujianyi athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT wangshaohong athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT lienmin athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT xuliyan athreeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT caohuihui threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT zhangshiyi threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT shenjinhui threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT wuzhiyong threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT wujianyi threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT wangshaohong threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT lienmin threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma
AT xuliyan threeproteinsignatureandclinicaloutcomeinesophagealsquamouscellcarcinoma